Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 15, 2023
March 01, 2023 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., March 01, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Innovation Pharmaceuticals Visits BeaMed; New StingRay Laser System for Epilepsy and Brain Tumors Moving Toward FDA Submission
February 23, 2023 08:00 ET
|
Innovation Pharmaceuticals Inc
WAKEFIELD, MA, Feb. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company and minority stakeholder in BT...
Catalyst Pharmaceuticals to Ring the Nasdaq Closing Bell in Honor of International Rare Disease Day
February 22, 2023 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
Spotlight On Raising Awareness for Rare Diseases on February 28, 2023 Celebrating the Tireless Contributions of Patients and Advocates who Work with the Biotech Industry to Bring New Treatments to...
Neurona Therapeutics Announces FDA Clearance of Expanded Inclusion Criteria for Phase I/II Clinical Trial of NRTX-1001 Regenerative Cell Therapy in Patients with Dominant Hemisphere Drug-Resistant Focal Epilepsy
February 14, 2023 08:00 ET
|
Neurona Therapeutics
NRTX-1001 administration is well-tolerated and shows seizure reduction of >90% in the first two patients at six- and three-months post-treatment, respectively Data & Safety Monitoring Board...
Epilepsy Market Size to Surpass USD 590.2 Million by 2030 at 7.20% CAGR – Report by Market Research Future (MRFR)
February 08, 2023 10:00 ET
|
Market Research Future
New York, USA, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Epilepsy Market Overview According to a Comprehensive Research Report by Market Research Future (MRFR), “Epilepsy Market Information By Condition,...
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
February 07, 2023 08:00 ET
|
Praxis Precision Medicines, Inc.
Ulixacaltamide (PRAX-944) Phase 2b Essential1 study topline results for essential tremor expected in 1Q23; Praxis to enter quiet period following market close on Thursday, February 9 Topline...
Epilepsy with Myoclonic-Atonic Seizures Therapeutics Market is Expected to Reach US$ 82.3 billion by 2030, Growth Plus Reports
January 31, 2023 05:20 ET
|
Growth Plus Reports
Newark, New Castle, USA, Jan. 31, 2023 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, global epilepsy with myoclonic-atonic seizures therapeutics market is...
Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® (Perampanel) CIII
January 25, 2023 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
Strengthens its Commercial Portfolio with the First and Only AMPA Receptor Antagonist Marketed Product for Epilepsy Bolsters Presence in Neuroscience Expected to be Accretive in 2023 ...
Global Neuromonitoring Devices Market Anticipated to Generate a Revenue of $10,276.0 Million and Rise at a CAGR of 7.24% during the Analysis Period from 2022 to 2030 [210-Pages] | Details by Research Dive
January 19, 2023 09:02 ET
|
Research Dive
New York, USA, Jan. 19, 2023 (GLOBE NEWSWIRE) -- According to the report published by Research Dive, the global neuromonitoring devices market is expected to generate $10,276.0 million in revenue...
Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd
December 19, 2022 16:10 ET
|
Catalyst Pharmaceuticals, Inc.
Acquisition Expands The Company’s Commercial Portfolio With An Established U.S. Marketed Product Company Remains Dedicated To Growth Within Neurology Through Continued Active Business Development...